Long non-coding RNA mediated drug resistance in breast cancer

Singh, Deepshikha; Assaraf, Yehuda G.; Gacche, Rajesh N.

doi:10.1016/j.drup.2022.100851

Cited by 75 publications

(22 citation statements)

References 174 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hydrophobic small-molecule chemotherapy drugs are ejected from cancer cells by ABC transporters, which make up a superfamily of over 48 ABC transporters identified in human genes. P-glycoprotein (ABCB1), ABC efflux transporter protein MRP1 (ABCC1), and breast cancer resistance protein (BCRP) (ABCG2), among other drug efflux transporters, have been identified as important mediators of MDR in cancer cells [160]. Recent studies have focused on the roles of lncRNAs in MDR in different cancer types.…”

Section: The Role Of Lncrnas In Cancer Therapy Resistancementioning

confidence: 99%

Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update

Bayraktar

Oztatlici

et al. 2023

ncRNA

View full text Add to dashboard Cite

Since the discovery of the first microRNAs (miRNAs, miRs), the understanding of miRNA biology has expanded substantially. miRNAs are involved and described as master regulators of the major hallmarks of cancer, including cell differentiation, proliferation, survival, the cell cycle, invasion, and metastasis. Experimental data indicate that cancer phenotypes can be modified by targeting miRNA expression, and because miRNAs act as tumor suppressors or oncogenes (oncomiRs), they have emerged as attractive tools and, more importantly, as a new class of targets for drug development in cancer therapeutics. With the use of miRNA mimics or molecules targeting miRNAs (i.e., small-molecule inhibitors such as anti-miRS), these therapeutics have shown promise in preclinical settings. Some miRNA-targeted therapeutics have been extended to clinical development, such as the mimic of miRNA-34 for treating cancer. Here, we discuss insights into the role of miRNAs and other non-coding RNAs in tumorigenesis and resistance and summarize some recent successful systemic delivery approaches and recent developments in miRNAs as targets for anticancer drug development. Furthermore, we provide a comprehensive overview of mimics and inhibitors that are in clinical trials and finally a list of clinical trials based on miRNAs.

show abstract

Section: The Role Of Lncrnas In Cancer Therapy Resistancementioning

confidence: 99%

Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update

Bayraktar

Oztatlici

et al. 2023

ncRNA

View full text Add to dashboard Cite

show abstract

“…In this regard, exosomal ncRNAs have a remarkable impact on a variety of tumor biology-related processes, including tumor growth, metastasis, migration, and drug resistance. Recently, it has been discovered that exosomal ncRNAs, particularly exosomal miRNAs, lncRNAs, and circRNAs, are involved in BC regulatory mechanisms ( Chen et al, 2021 ; Singh et al, 2022 ). Exclusively, the latest findings on the crosstalk between exosomal ncRNAs (miRNAs, lncRNAs, and circRNAs) and BC drug resistance will be reviewed in the upcoming sections ( Figures 1 , 2 ).…”

Section: Molecular Mechanisms By Which Exosomal Ncrnas Interfere With...mentioning

confidence: 99%

The landscape of exosomal non-coding RNAs in breast cancer drug resistance, focusing on underlying molecular mechanisms

et al. 2023

View full text Add to dashboard Cite

Breast cancer (BC) is the most common malignancy among women worldwide. Like many other cancers, BC therapy is challenging and sometimes frustrating. In spite of the various therapeutic modalities applied to treat the cancer, drug resistance, also known as, chemoresistance, is very common in almost all BCs. Undesirably, a breast tumor might be resistant to different curative approaches (e.g., chemo- and immunotherapy) at the same period of time. Exosomes, as double membrane-bound extracellular vesicles 1) secreted from different cell species, can considerably transfer cell products and components through the bloodstream. In this context, non-coding RNAs (ncRNAs), including miRNAs, long ncRNAs (lncRNAs), and circular RNAs (circRNAs), are a chief group of exosomal constituents with amazing abilities to regulate the underlying pathogenic mechanisms of BC, such as cell proliferation, angiogenesis, invasion, metastasis, migration, and particularly drug resistance. Thereby, exosomal ncRNAs can be considered potential mediators of BC progression and drug resistance. Moreover, as the corresponding exosomal ncRNAs circulate in the bloodstream and are found in different body fluids, they can serve as foremost prognostic/diagnostic biomarkers. The current study aims to comprehensively review the most recent findings on BC-related molecular mechanisms and signaling pathways affected by exosomal miRNAs, lncRNAs, and circRNAs, with a focus on drug resistance. Also, the potential of the same exosomal ncRNAs in the diagnosis and prognosis of BC will be discussed in detail.

show abstract

“…Hence, optimizing treatment outcomes for any disease is only possible with full knowledge of the underlying mechanisms. In this regard, recent studies involving lncRNAs have substantially contributed to understanding the cancer (Li et al, 2022b;Singh et al, 2022;Zhong et al, 2022). However, exploiting the potential of lncRNAs as biomarkers and therapeutic targets is just the beginning (Mirzaei et al, 2022).…”

Section: Therapeutic Importance Of Lncrna Linc-pintmentioning

confidence: 99%

Clinical implications of lncRNA LINC-PINT in cancer

Bukhari

Khan

et al. 2023

Front. Mol. Biosci.

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) possess the potential for therapeutic targeting to treat many disorders, including cancers. Several RNA-based therapeutics (ASOs and small interfering RNAs) have gained FDA approval over the past decade. And with their potent effects, lncRNA-based therapeutics are of emerging significance. One important lncRNA target is LINC-PINT, with its universalized functions and relationship with the famous tumor suppressor gene TP53. Establishing clinical relevance, much like p53, the tumor suppressor activity of LINC-PINT is implicated in cancer progression. Moreover, several molecular targets of LINC-PINT are directly or indirectly used in routine clinical practice. We further associate LINC-PINT with immune responses in colon adenocarcinoma, proposing the potential utility of LINC-PINT as a novel biomarker of immune checkpoint inhibitors. Collectively, current evidence suggests LINC-PINT can be considered for use as a diagnostic/prognostic marker for cancer and several other diseases.

show abstract

Long non-coding RNA mediated drug resistance in breast cancer

Cited by 75 publications

References 174 publications

Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update

Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update

The landscape of exosomal non-coding RNAs in breast cancer drug resistance, focusing on underlying molecular mechanisms

Clinical implications of lncRNA LINC-PINT in cancer

Contact Info

Product

Resources

About